Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Current Deferred Revenue (2017 - 2025)

Historic Current Deferred Revenue for Regen BioPharma (RGBPP) over the last 6 years, with Q4 2025 value amounting to $1.3 million.

  • Regen BioPharma's Current Deferred Revenue fell 882.85% to $1.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 million, marking a year-over-year decrease of 882.85%. This contributed to the annual value of $1.3 million for FY2025, which is 863.79% down from last year.
  • Regen BioPharma's Current Deferred Revenue amounted to $1.3 million in Q4 2025, which was down 882.85% from $1.3 million recorded in Q3 2025.
  • Regen BioPharma's Current Deferred Revenue's 5-year high stood at $1.9 million during Q2 2021, with a 5-year trough of $1.3 million in Q4 2025.
  • For the 4-year period, Regen BioPharma's Current Deferred Revenue averaged around $1.5 million, with its median value being $1.4 million (2024).
  • As far as peak fluctuations go, Regen BioPharma's Current Deferred Revenue plummeted by 795.11% in 2024, and later tumbled by 882.85% in 2025.
  • Quarter analysis of 4 years shows Regen BioPharma's Current Deferred Revenue stood at $1.9 million in 2021, then decreased by 15.14% to $1.6 million in 2023, then fell by 9.94% to $1.4 million in 2024, then fell by 8.83% to $1.3 million in 2025.
  • Its Current Deferred Revenue was $1.3 million in Q4 2025, compared to $1.3 million in Q3 2025 and $1.4 million in Q2 2025.